We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$1.24M
Cap. Flow
+$25.3M
Cap. Flow %
21.92%
Top 10 Hldgs %
67.87%
Holding
48
New
20
Increased
9
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$9.08M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$6.43M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$5.79M
4
TERN
Terns Pharmaceuticals
TERN
+$4.55M
5
URGN icon
UroGen Pharma
URGN
+$3.61M

Top Sells

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$6.2M
2
CAPR icon
Capricor Therapeutics
CAPR
+$4.94M
3
CYTK icon
Cytokinetics
CYTK
+$4.49M
4
ETNB
89bio
ETNB
+$3.81M
5
NKTX icon
Nkarta
NKTX
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
26
Verastem
VSTM
$530M
$1.09M 0.94%
+209,889
New +$827K
ETNB
27
DELISTED
89bio
ETNB
$1.04M 0.9%
132,982
-462,221
-78% -$3.81M
ZBIO
28
Zenas BioPharma
ZBIO
$1.86B
$914K 0.79%
111,605
– –
CAPR icon
29
Capricor Therapeutics
CAPR
$1.13B
$762K 0.66%
55,229
-282,118
-84% -$4.94M
KYTX icon
30
Kyverna Therapeutics
KYTX
$453M
$681K 0.59%
+182,177
New +$873K
RZLT icon
31
Rezolute
RZLT
$444M
$604K 0.52%
+123,184
New +$621K
IPSC icon
32
Century Therapeutics
IPSC
$406M
$468K 0.4%
+462,963
New +$630K
ZURA icon
33
Zura Bio
ZURA
$518M
$467K 0.4%
186,943
+30,317
+19% +$108K
EYPT icon
34
EyePoint Inc
EYPT
$1.12B
$368K 0.32%
+49,375
New +$460K
AXSM icon
35
Axsome Therapeutics
AXSM
$11.8B
$361K 0.31%
+4,268
New +$392K
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$12.8B
$348K 0.3%
+1,129
New +$318K
LXEO icon
37
Lexeo Therapeutics
LXEO
$368M
$346K 0.3%
+52,616
New +$414K
CLYM
38
Climb Bio
CLYM
$727M
$177K 0.15%
98,160
+64,336
+190% +$233K
LSB
39
DELISTED
LakeShore Biopharma
LSB
$106K 0.09%
30,792
– –
ALLO icon
40
Allogene Therapeutics
ALLO
$618M
– –
-478,115
Closed -$1.34M
BMEA icon
41
Biomea Fusion
BMEA
$92.5M
– –
-83,554
Closed -$844K
CGEM icon
42
Cullinan Oncology
CGEM
$1.09B
– –
-20,840
Closed -$349K
CRBP icon
43
Corbus Pharmaceuticals
CRBP
$167M
– –
-25,401
Closed -$524K
IMVT icon
44
Immunovant
IMVT
$8.27B
– –
-12,447
Closed -$355K
NKTX icon
45
Nkarta
NKTX
$186M
– –
-740,294
Closed -$3.35M
SYRE icon
46
Spyre Therapeutics
SYRE
$8.7B
– –
-37,287
Closed -$1.1M
TRML
47
DELISTED
Tourmaline Bio
TRML
– –
-29,104
Closed -$748K
ZLAB icon
48
CALL
Zai Lab
ZLAB
$2.28B
– –
-100,000
Closed -$2.41M
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Superstring Capital Management held 48 positions worth $115M, up 1.1% from $114M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Superstring Capital Management deployed $25.3M of net new capital in Q4 2024, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Cogent Biosciences: 910,865 shares worth $7.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Zai Lab, an estimated $6.2M trimmed.

  • Superstring Capital Management's largest Q4 2024 buy was Cogent Biosciences: 910,865 shares worth $7.1M.
  • Superstring Capital Management added most to Oric Pharmaceuticals in Q4 2024, an estimated $5.79M increase.
  • Superstring Capital Management's biggest Q4 2024 reduction was Zai Lab, cutting an estimated $6.2M.
  • Superstring Capital Management fully exited Nkarta in Q4 2024, selling an estimated $3.35M.
  • Superstring Capital Management's ten largest holdings make up 68% of its $115M portfolio in Q4 2024.
  • Superstring Capital Management opened 20 new positions and closed 9 in Q4 2024.
  • Superstring Capital Management's portfolio value rose 1.1% quarter-over-quarter to $115M.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.